Alfred Ford, Jr. Sells 5,936 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) insider Alfred Ford, Jr. sold 5,936 shares of the stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $22.76, for a total transaction of $135,103.36. Following the completion of the sale, the insider directly owned 127,535 shares in the company, valued at approximately $2,902,696.60. This represents a 4.45% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 5.1%

KMTS traded up $1.16 on Monday, reaching $23.99. The company’s stock had a trading volume of 373,728 shares, compared to its average volume of 404,856. The company has a market capitalization of $1.41 billion, a price-to-earnings ratio of -9.91 and a beta of 0.58. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a fifty-two week low of $14.10 and a fifty-two week high of $30.00. The stock has a 50 day moving average of $22.62 and a two-hundred day moving average of $22.48.

Get Kestra Medical Technologies alerts:

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last issued its earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. As a group, analysts forecast that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of KMTS. California State Teachers Retirement System increased its holdings in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after purchasing an additional 7,844 shares during the period. The Manufacturers Life Insurance Company grew its position in Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock valued at $1,844,000 after buying an additional 5,731 shares during the last quarter. Quantinno Capital Management LP purchased a new position in Kestra Medical Technologies in the 1st quarter valued at $431,000. Sei Investments Co. increased its stake in Kestra Medical Technologies by 22.6% in the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after buying an additional 43,753 shares during the period. Finally, Spartan Wealth Advisory Services LLC purchased a new position in Kestra Medical Technologies during the 1st quarter worth $603,000.

Analyst Ratings Changes

A number of research firms recently issued reports on KMTS. Weiss Ratings downgraded Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 16th. The Goldman Sachs Group decreased their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wall Street Zen cut shares of Kestra Medical Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating on the stock. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kestra Medical Technologies currently has a consensus rating of “Hold” and a consensus price target of $27.83.

Read Our Latest Stock Analysis on Kestra Medical Technologies

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

Featured Stories

• Five stocks we like better than Kestra Medical Technologies
• SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
• Why Rare Earth Processing Could Be the Real 2027 Opportunity
• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
• TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.